Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer.
Journal: Advances in therapy
Published: January 26, 2026
A 10-year retrospective review of mushroom exposures reported to the United Kingdom National Poisons Information Service between 2013 and 2022.
Journal: Clinical toxicology (Philadelphia, Pa.)
Published: June 27, 2025
Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial.
Journal: Clinical lymphoma, myeloma & leukemia
Published: December 17, 2024
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison.
Journal: Leukemia & lymphoma
Published: February 12, 2024
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece.
Journal: Clinical lymphoma, myeloma & leukemia
Published: January 02, 2024
Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany.
Journal: Bone marrow transplantation
Published: August 14, 2023
Showing 1-6 of 6
Last Updated: 09/26/2026